

WEDNESDAY 20th MARCH 2013 COMMENCING 10.30 AM

(UNTIL 4.00 PM APPROX)

AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN

AGENDA

- | | | |
|----|--|--|
| | | Enclosure |
| 1. | Welcome and introduction | |
| 2. | Apologies | |
| 3. | Declarations of interest | |
| 4. | Chairman's report (verbal update) | |
| 5. | Minutes of previous meeting | 1/AWMSG/0313 |
| 6. | Appraisal 1
Linagliptin (Trajenta[®]▼) for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:
<u>as monotherapy</u> <ul style="list-style-type: none"> • in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; <u>as combination therapy</u> <ul style="list-style-type: none"> • in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control; • in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control; and • in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control. | 2/AWMSG/0313
Appendices |
| 7. | Appraisal 2
Pazopanib (Votrient[®]) for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy | 3/AWMSG/0313
Appendices |
| 8. | Appraisal 3
Glycopyrronium bromide (Seebri Breezhaler[®]) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease | 4/AWMSG/0313
Appendices |

Proceedings held in public will close and, to protect commercial confidentiality, Appraisal 4 will be conducted in private with representatives of the applicant pharmaceutical company in attendance

- | | | |
|-----|---|--|
| 9. | Appraisal 4
Aztreonam lysine (Cayston®) for the suppressive therapy of chronic pulmonary infections due to <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis aged 6 years and older | 5/AWMSG/0313
Appendices |
| 10. | AWPAG update (draft minutes of January 2013 meeting) | 6/AWMSG/0313 |
| 11. | AWMSG National Prescribing Indicators 2013–2014: Supporting information for prescribers | 7/AWMSG/0313 |
| 12. | CEPP National Audit: Focus on Antibiotic Prescribing | 8/AWMSG/0313 |
| 13. | Date of next meeting:
Wednesday 8th May 2013 in Abergavenny | |